Modality
Multispecific
MOA
TYK2i
Target
FcRn
Pathway
Checkpoint
EpilepsyLGS
Development Pipeline
Preclinical
Jun 2022
→ Dec 2031
PreclinicalCurrent
NCT04787087
1,617 pts·LGS
2022-06→2031-12·Completed
1,617 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-12-095.7y awayInterim· LGS
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Preclinical
Complet…
Catalysts
Interim
2031-12-09 · 5.7y away
LGS
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04787087 | Preclinical | LGS | Completed | 1617 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET |